AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety
Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months